HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Direct Seller Neora Pushes Back On FTC Pyramid Scheme, False Claims Complaint

Executive Summary

Firm says "we refuse to be bullied into a settlement" and FTC conflates legal MLMs with pyramid schemes by alleging every MLM paying incentives "for recruitment of participants” is a pyramid scheme. Separate firm supplying ingredient for brain health supplement agreed to settlement of FTC false ad complaint.

You may also be interested in...



Supplements Mixed With Direct Selling A Recipe Ripe For Cooking US FTC Regulation Violations

Doesn’t take long to find health and wellness product marketers on list of direct sellers or find firms offering those products in the FTC's history of enforcement actions in the sector. 

US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Advocare Out Of Pyramid Scheme, Into Single-Tier Sales Under FTC Settlement

Advocare "is admitting that it operated as a pyramid and they are agreeing to no longer operate in multi-level marketing," says FTC Consumer Protection direct Andrew Smith. Firm is marketing sports, weight-loss and wellness products on a single-tier model with distributors' compensation based on selling directly to end-users.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel